Drug
Peramivir
Peramivir: highest development phase Phase 3, developed by BioCryst Pharmaceuticals. 7 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- BioCryst Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Peramivir NCT00957996 | Phase 3 | Seasonal Influenza |
| Peramivir NCT02635724 | Phase 3 | Influenza |
| Peramivir 150mg NCT00486980 | Phase 3 | Influenza |
| Peramivir NCT00610935 | Phase 3 | Influenza |
| Peramivir NCT01224795 | Phase 3 | Influenza |
| Peramivir NCT02665351 | Phase 2/3 | Influenza |
| Peramivir NCT00705406 | Phase 2 | Acute, Uncomplicated Human Influenza |
Latest
No recent events.
Follow Peramivir on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.